BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 36059482)

  • 1. The contribution of the intestinal microbiome to immune recovery after HCT.
    Wolfe AE; Markey KA
    Front Immunol; 2022; 13():988121. PubMed ID: 36059482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic hematopoietic cell transplantation, the microbiome, and graft-versus-host disease.
    van Lier YF; Vos J; Blom B; Hazenberg MD
    Gut Microbes; 2023; 15(1):2178805. PubMed ID: 36794370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the intestinal microbiota in allogeneic HCT: clinical associations and preclinical mechanisms.
    Nguyen CL; Docampo MD; van den Brink MR; Markey KA
    Curr Opin Genet Dev; 2021 Feb; 66():25-35. PubMed ID: 33388483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease.
    Staffas A; Burgos da Silva M; van den Brink MR
    Blood; 2017 Feb; 129(8):927-933. PubMed ID: 27940475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microbiome: An Emerging New Frontier in Graft-Versus-Host Disease.
    Kumari R; Palaniyandi S; Hildebrandt GC
    Dig Dis Sci; 2019 Mar; 64(3):669-677. PubMed ID: 30523482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease.
    Mohamed FA; Thangavelu G; Rhee SY; Sage PT; O'Connor RS; Rathmell JC; Blazar BR
    Front Immunol; 2021; 12():757836. PubMed ID: 34712243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor.
    Jiang H; Fu D; Bidgoli A; Paczesny S
    Front Immunol; 2021; 12():761448. PubMed ID: 34675938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
    Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of intestinal microbiota in antithymocyte globulin-based myeloablative allogeneic hematopoietic cell transplantation.
    Gu Z; Xiong Q; Wang L; Wang L; Li F; Hou C; Dou L; Zhu B; Liu D
    Cancer; 2022 Apr; 128(7):1402-1410. PubMed ID: 35077579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Fructo-Oligosaccharide Prebiotic Is Well Tolerated in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Dose-Escalation Trial.
    Andermann TM; Fouladi F; Tamburini FB; Sahaf B; Tkachenko E; Greene C; Buckley MT; Brooks EF; Hedlin H; Arai S; Mackall CL; Miklos D; Negrin RS; Fodor AA; Rezvani AR; Bhatt AS
    Transplant Cell Ther; 2021 Nov; 27(11):932.e1-932.e11. PubMed ID: 34274493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
    Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbiome and diversity indices during blood stem cells transplantation - new perspectives?
    Parco S; Benericetti G; Vascotto F; Palmisciano G
    Cent Eur J Public Health; 2019 Dec; 27(4):335-339. PubMed ID: 31951695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
    Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
    Front Immunol; 2021; 12():785774. PubMed ID: 34987512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single strain of Bacteroides fragilis protects gut integrity and reduces GVHD.
    Sofi MH; Wu Y; Ticer T; Schutt S; Bastian D; Choi HJ; Tian L; Mealer C; Liu C; Westwater C; Armeson KE; Alekseyenko AV; Yu XZ
    JCI Insight; 2021 Feb; 6(3):. PubMed ID: 33554953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation.
    Baumeister SHC; Rambaldi B; Shapiro RM; Romee R
    Front Immunol; 2020; 11():191. PubMed ID: 32117310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.
    Kharfan-Dabaja M; Mhaskar R; Reljic T; Pidala J; Perkins JB; Djulbegovic B; Kumar A
    Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010280. PubMed ID: 25061777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.
    Shah NN; Loeb DM; Khuu H; Stroncek D; Ariyo T; Raffeld M; Delbrook C; Mackall CL; Wayne AS; Fry TJ
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2149-2154. PubMed ID: 27634018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
    Chang YJ; Zhao XY; Huang XJ
    Front Immunol; 2018; 9():3041. PubMed ID: 30619371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation.
    Peled JU; Devlin SM; Staffas A; Lumish M; Khanin R; Littmann ER; Ling L; Kosuri S; Maloy M; Slingerland JB; Ahr KF; Porosnicu Rodriguez KA; Shono Y; Slingerland AE; Docampo MD; Sung AD; Weber D; Alousi AM; Gyurkocza B; Ponce DM; Barker JN; Perales MA; Giralt SA; Taur Y; Pamer EG; Jenq RR; van den Brink MRM
    J Clin Oncol; 2017 May; 35(15):1650-1659. PubMed ID: 28296584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.